Key result
Transcatheter aortic valve implantation is a recommended therapeutic intervention for patients with severe aortic stenosis who are deemed high risk or inoperable, with expanding indications.
This review summarizes the current guidelines, evidence, complications, and future perspectives of TAVI for severe aortic stenosis.
TAVI expansion in severe AS supports broader use; leaves open long-term durability in lower-risk groups.
Transcatheter aortic valve implantation (TAVI) was first used in clinical practice in 2002. Since 2002, there has been a rapid increase in TAVI activity in patients with symptomatic severe aortic stenosis. This has been supported by systematic randomized data comparing TAVI against the gold standard treatment for the last 50 years' surgical aortic valve replacement. TAVI is now currently a recommended therapeutic intervention in the treatment of severe aortic stenosis patients who are deemed either high risk or inoperable. The indications for TAVI continue to expand. Within this review we will focus on the current guidelines for TAVI, the evidence for it, the complications of TAVI, postprocedure care, the technology available to clinicians now and finally the future perspectives for TAVI.
No takes yet. Share an insight, caveat, or question.
Mariathas et al. (2017) conducted a review in Symptomatic severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement was evaluated. Transcatheter aortic valve implantation is a recommended therapeutic intervention for patients with severe aortic stenosis who are deemed high risk or inoperable, with expanding indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: